These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3545428)

  • 41. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Jagannath S; Armitage JO; Dicke KA; Tucker SL; Velasquez WS; Smith K; Vaughan WP; Kessinger A; Horwitz LJ; Hagemeister FB
    J Clin Oncol; 1989 Feb; 7(2):179-85. PubMed ID: 2644397
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Influence of graft-versus-host disease on outcome following allogeneic transplantation with radiation-free preparative therapy in patients with advanced leukemia.
    Copelan EA; Penza SL; Elder PJ; Belt PS; Scholl MD; Hehmeyer DM; Ezzone SA; Bechtel TP; Avalos BR
    Bone Marrow Transplant; 1996 Nov; 18(5):907-11. PubMed ID: 8932844
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Total body irradiation, thiotepa, and cyclophosphamide as a conditioning regimen for children with acute lymphoblastic leukemia in first or second remission undergoing bone marrow transplantation with HLA-identical siblings.
    Zecca M; Pession A; Messina C; Bonetti F; Favre C; Prete A; Cesaro S; Porta F; Mazzarino I; Giorgiani G; Rondelli R; Locatelli F
    J Clin Oncol; 1999 Jun; 17(6):1838-46. PubMed ID: 10561223
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation.
    Geller RB; Myers S; Devine S; Larson RA; Williams SF; Park CL; O'Toole K; Chandler C; Topper RL
    Bone Marrow Transplant; 1992 Jan; 9(1):41-7. PubMed ID: 1543948
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma.
    Rossi HA; Becker PS; Emmons RV; Westervelt P; Levy W; Liu Q; Clark Y; Ballen K
    Bone Marrow Transplant; 2003 Mar; 31(6):441-6. PubMed ID: 12665838
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy.
    Phillips GL; Shepherd JD; Barnett MJ; Lansdorp PM; Klingemann HG; Spinelli JJ; Nevill TJ; Chan KW; Reece DE
    J Clin Oncol; 1991 Oct; 9(10):1880-8. PubMed ID: 1919638
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Non-supralethal mitobronitol/cytarabine/cyclophosphamide conditioning without irradiation before bone marrow transplantation for accelerated chronic granulocytic leukemia: apparent absence of acute graft-versus-host disease.
    Kelemen E; Jakab K; Váradi G; Jánossa M; Földi J; Dénes R
    Leukemia; 1993 Jul; 7(7):939-45. PubMed ID: 8321045
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Autologous peripheral blood stem cell transplantation with BCVAC conditioning in childhood acute myeloid leukemia.
    Kang HJ; Shin HY; Choi HS; Han KS; Ahn HS
    Bone Marrow Transplant; 2004 Mar; 33(5):471-6. PubMed ID: 14716339
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Jagannath S; Dicke KA; Armitage JO; Cabanillas FF; Horwitz LJ; Vellekoop L; Zander AR; Spitzer G
    Ann Intern Med; 1986 Feb; 104(2):163-8. PubMed ID: 3511811
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Peripheral blood progenitor cell mobilization with Dexa-Beam/G-CSF, ether lipid purging, and autologous transplantation after high-dose CBV treatment: a safe and effective regimen in patients with poor risk malignant lymphomas.
    Knauf WU; Koenigsmann MP; Notter M; Hoppe B; Reufi B; Oberberg D; Thiel E; Berdel WE
    Leuk Lymphoma; 1996 Oct; 23(3-4):305-11. PubMed ID: 9031111
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma.
    Meisenberg BR; Ross M; Vredenburgh JJ; Jones R; Shpall EJ; Seigler HF; Coniglio DM; Wu K; Peters WP
    J Natl Cancer Inst; 1993 Jul; 85(13):1080-5. PubMed ID: 8515495
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Allogeneic marrow transplantation for refractory Hodgkin's disease.
    Phillips GL; Reece DE; Barnett MJ; Connors JM; Fay JW; Herzig GP; Herzig RH; Klingemann HG; Shepherd JD; Wolff SN
    J Clin Oncol; 1989 Aug; 7(8):1039-45. PubMed ID: 2474058
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term endocrine toxicity of myeloablative treatment followed by autologous bone marrow/blood derived stem cell transplantation in patients with malignant lymphohematopoietic disorders.
    Keilholz U; Körbling M; Fehrentz D; Bauer H; Hunstein W
    Cancer; 1989 Aug; 64(3):641-5. PubMed ID: 2568164
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes.
    Locatelli F; Pession A; Bonetti F; Maserati E; Prete L; Pedrazzoli P; Zecca M; Prete A; Paolucci P; Cazzola M
    Leukemia; 1994 May; 8(5):844-9. PubMed ID: 8182940
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of total body irradiation as based on the comparison of preparation regimens for allogeneic bone marrow transplantation for acute leukemia in first complete remission.
    Inoue T; Ikeda H; Yamazaki H; Tang JT; Song C; Teshima T; Murayama S; Ohtani M; Shibata H; Masaoka T
    Strahlenther Onkol; 1993 Apr; 169(4):250-5. PubMed ID: 8488461
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bone marrow transplantation for childhood acute myelogenous leukemia.
    Lin KH; Jou ST; Chen RL; Lin DT; Lin KS
    Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi; 1994; 35(5):415-22. PubMed ID: 7942028
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of autologous bone marrow transplantation in acute leukemia.
    Dicke KA; Jagannath S; Walters RS; Horwitz LJ; Spitzer G
    Ann N Y Acad Sci; 1987; 511():468-72. PubMed ID: 3326476
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.
    Worth L; Tran H; Petropoulos D; Culbert S; Mullen C; Roberts W; Przepiorka D; Chan K
    Bone Marrow Transplant; 1999 Nov; 24(9):947-52. PubMed ID: 10556952
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation.
    Blume KG; Long GD; Negrin RS; Chao NJ; Kusnierz-Glaz C; Amylon MD
    Bone Marrow Transplant; 1994; 14 Suppl 4():S9-10. PubMed ID: 7728133
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intensive therapy and autotransplantation in Hodgkin's disease.
    Reece DE; Phillips GL
    Stem Cells; 1994 Sep; 12(5):477-93. PubMed ID: 7804123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.